Neuraminidase inhibitors are a cornerstone of influenza pandemic preparedness before vaccines can be mass-produced and thus a neuraminidase inhibitor-resistant pandemic is a serious threat to public health. Earlier work has demonstrated the potential for development and persistence of oseltamivir resistance in influenza A viruses exposed to environmentally relevant water concentrations of the drug when infecting mallards, the natural influenza reservoir that serves as the genetic base for human pandemics. As zanamivir is the major second-line neuraminidase inhibitor treatment, this study aimed to assess the potential for development and persistence of zanamivir resistance in an in vivo mallard model; especially important as zanamivir will probably be increasingly used. Our results indicate less potential for development and persistence of resistance due to zanamivir than oseltamivir in an environmental setting. This conclusion is based on: (1) the lower increase in zanamivir IC 50 conferred by the mutations caused by zanamivir exposure (2-17-fold); (2) the higher zanamivir water concentration needed to induce resistance (at least 10 µg l À1 ); (3) the lack of zanamivir resistance persistence without drug pressure; and (4) the multiple resistance-related substitutions seen during zanamivir exposure (V116A, A138V, R152K, T157I and D199G) suggesting lack of one straight-forward evolutionary path to resistance. Our study also adds further evidence regarding the stability of the oseltamivir-induced substitution H275Y without drug pressure, and demonstrates the ability of a H275Y-carrying virus to acquire secondary mutations, further boosting oseltamivir resistance when exposed to zanamivir. Similar studies using influenza A viruses of the N2-phylogenetic group of neuraminidases are recommended.
INTRODUCTION
Influenza A virus (IAV) causes disease in numerous mammalian and avian species, and in the human population both seasonal and pandemic outbreaks of respiratory disease occur. The influenza pandemic with most causalities, the Spanish Flu, resulted in 50-100 million deaths, and the most recent pandemic, the pandemic H1N1 in 2009 caused an estimated 200 000 deaths [1, 2] . Birds constitute the natural reservoir for IAVs, and all currently circulating IAVs have origins from avian viruses, with the exception of a few lineages that likely originate from bats [3, 4] . Within the avian reservoir, dabbling ducks, particularly mallards (Anas platyrhynchos), are central to avian influenza virus (AIV) epidemiology and ecology [3] . In this natural host, IAV infection is primarily intestinal and causes no clinical signs of disease [3, 5] . In contrast, propagation of low-pathogenic AIV (LPAIV) in poultry may result in the development of highly pathogenic AIV (HPAIV) causing severe respiratory disease and high mortality [6] . Influenza outbreaks with HPAIV severely deteriorate animal welfare and cause substantial financial losses due to morbidity, mortality and culling as an outbreak control effort.
HPAIV infection in humans, such as H5N1 or H7N9, is rare but carries a much higher case fatality rate than disease by human-adapted influenza viruses [7, 8] . Human infection with IAVs containing genetic material originally derived from wild birds can occur by two separate mechanisms; either by reassortment of gene segments with a human-adapted virus or by direct transmission of an AIV that has acquired the ability to infect humans [9, 10] . It is notable that all influenza pandemics in humans spanning the last 100 years were caused by antigenically novel IAVs originated through reassortment events involving genetic elements originating from avian viruses [9, 11] .
Neuraminidase inhibitors (NAIs) constitute the most important class of anti-influenza drugs. They bind to the neuraminidase (NA) enzyme active site, resulting in decreased enzyme function and impaired release of newly formed virions from the infected cell [12] . Two NAIs are commercially available world-wide, oseltamivir (Tamiflu) and zanamivir (ZA, Relenza). Oseltamivir is preferably used due to its convenient oral formulation, whereas ZA needs to be inhaled or injected (the injectable formulation is in late-stage clinical trials) [13, 14] . NAIs are of particular importance as many countries have stockpiled these drugs (especially oseltamivir) as the first line of defence in the case of an IAV pandemic before vaccines can be mass-produced [15] . Widespread oseltamivir resistance in human IAVs was first seen in H1N1 during the 2007-08 season. The resistance was conferred by the H275Y substitution (N1-numbering, consistently used hereafter) in NA and spread without relation to drug exposure, following a number of permissive substitutions over a prolonged time [16] [17] [18] . Regarding ZA, in vitro experiments have identified several NA-substitutions conferring drug resistance, such as E119G, Q136K and D199G in N1 viruses and R293K in N2 viruses, though there are few reports on clinical ZA resistance [19] [20] [21] .
The NAIs excreted from treated patients are not efficiently removed in conventional waste water treatment plants and the active metabolite of oseltamivir, oseltamivir carboxylate (OC), and ZA are only slowly degraded in the environment [22] [23] [24] . Thus, in several studies, NAIs have been detected in river water with levels up to 865 ng l À1 of OC and 59 ng l À1 of ZA [25, 26] . In these water environments, wild waterfowl harbouring intestinal LPAIVs may be exposed to the drugs, potentially allowing for the emergence of NAI-resistant AIVs in the environment [27] . Results from previous in vivo mallard studies mimicking natural exposure to OC support the significance of this potential route to OC resistance. Specifically, in a H1N1 LPAIV, OC resistance through the H275Y substitution occurred at a concentration of 0.95 µg l À1 of OC in the water of mallards, and the resistance persisted following removal of drug pressure [28, 29] . Additional resistance development has been observed when mallards infected with an H5N2 LPAIV were exposed to 1 µg l À1 of OC (E119V [30] ), an H7N9 LPAIV to 2.5 µg l À1 of OC (I223T [31] ) and an H6N2 LPAIV to 12 µg l À1 of OC (R293K [32, 33] ). However, neither the E119V substitution in H5N2 nor the R293K in the H6N2 virus were maintained in the absence of drug pressure.
Considering the introduction of an intravenous ZA formulation and the potential of OC-resistant human IAVs, ZA use and thus ZA levels in the environment, may increase rapidly in the future. It is therefore imperative to investigate if ZA can induce resistance in IAVs infecting the natural host, as has been demonstrated for OC. As ZA prescription is still limited, the results can contribute to guide a prudent use of this important pharmaceutical before it is widely used. NAIs are a cornerstone in influenza pandemic preparedness plans globally, therefore, the development of NAI-resistant LPAIVs in the environment and the potential transmission of resistance to human IAVs would be of major human health concern. In order for an LPAIV to constitute a problem in this sense, two basic criteria are required: firstly, that resistance can develop when waterfowl carrying LPAIVs are exposed to low, environmentally relevant, concentrations of the drug, and, secondly, that the resistance, once it has evolved, can persist without drug pressure (as influenza outbreaks are sporadic and NAIs are not constantly used). These phenomena have been demonstrated for OC [28] [29] [30] [31] [32] , raising the question if the same is true for the second-line NAI ZA. This study comprises several experiments in an in vivo mallard model to investigate both these aspects for an H1N1 LPAIV isolated from a wild mallard and its OC-resistant counterpart H1N1/H275Y.
RESULTS

IAV infection
We used the following LPAIVs for inoculation: (a) A/mallard/Sweden/51833/2006 (H1N1), hereafter referred to as 51833/wt, that was originally isolated from a wild mallard; (b) the mutant A/mallard/Sweden/51833/2006 (H1N1)/NA-H275Y, hereafter referred to as 51833/H275Y, that was previously isolated from a mallard inoculated with 51833/wt and exposed to 80 µg l À1 of OC; and (c) viruses isolated during the study and used in follow-up experiments, referred to by their resistance-related substitution, e.g. 51833/V116A. A mallard model with successive introduction of influenzanaïve birds was used, see Fig. 1 (a-e) and Methods for details.
All birds used in experiments were initially immunologically naïve, i.e. they had no detectable antibodies against IAV and were PCR-negative for IAV prior to inclusion in the experiment. During the experiments, viral shedding in faeces was typically detected 1 day post inoculation (p.i.) or post introduction and never later than 3 days p.i. or post introduction. The shedding typically reached a maximum at 1-2 days and never later than 4 days p.i. or post introduction. Shedding patterns were similar to our previous IAV work on the mallard model [28, 29, 31, 32] .
Exposure experiments (wild-type H1N1) Three different exposure experiments were performed, using three different concentrations of ZA (Fig. 1a-c , details in Methods). In the first exposure experiment (1 µg l À1 ), 51833/wt was detected throughout the experiment, with no NA substitutions observed, indicating insufficient drug pressure for resistance development (Fig. 2a) . When increasing the concentration 10-fold (10 µg l À1 ), two different substitutions, R152K and D199G, emerged in the first generation of birds 3 and 4 days p.i., respectively, in mixed genotype with the wild-type. The substitutions were also detected in the second generation, but never outcompeted the wild-type sub-population (Fig. 2b) . When the ZA concentration was further raised 10-fold (100 µg l À1 ) in the last exposure experiment, three NA substitutions (V116A, A138V and T157I) emerged 2 days p.i., followed by the R152K substitution 4 days p.i. On a few occasions regarding V116A and A138V, no wild-type sub-population was detected by Sanger sequencing, but generally the substitutions were found in a mixed genotype population (Fig. 2c) . D199G, despite being detected in the second experiment (10 µg l À1 ), was not detected in the third experiment (100 µg l À1 ).
Persistence experiments (wild-type H1N1) In order to assess the persistence of each substitution that emerged in the exposure experiments, five isolates each representing one of the five substitutions were used for five separate persistence experiments ( Fig. 1d and Table 1 , details in Methods). For each substitution/experiment, for inoculation we selected the isolate with the highest proportion of substitution from the exposure experiments as detected by Sanger sequencing. R152K and D199G isolates were obtained from the 10 µg l À1 exposure experiment and V116A, A138V and T157I isolates from the 100 µg l À1 exposure experiment. Among these five isolates, the T157I variant dominated the In the 1 µg l À1 experiment, a total of eight birds were included, in the 10 and 100 µg l À1 experiments, four birds each were included. The birds were grouped two and two in generations. Two and four substitutions emerged in the 10 and 100 µg l À1 experiments respectively. One panel is given for each substitution and thus the 10 and 100 µg l À1 experiments contain two and four panels respectively but display the results of only one experiment with each zanamivir concentration. Abbreviations: days p.i.=days post inoculation, ZA=zanamivir. In the figure legend 'Wildtype' indicates only wild-type observed at the amino acid residue, 'Mixed' indicates the mixed genotype containing wild-type and relevant substitution in various proportions, and 'Dominant' indicates only relevant substitution observed at the residue. 'Neg/ns' indicates negative sample or no sequence acquired. 51833/T157I isolate completely but the other four contained mixed genotypes at the respective site of the substitution. The wild-type nucleotide was detected with a much lower peak in the electropherogram (representing a maximum of one-tenth of the height of the substitution's) suggesting dominance of the mutant genotype. However, it is important to note that Sanger sequencing does not provide a reliable quantitative measure of the different genotypes in a mixture and that 50 % inhibitory concentration (IC 50 ) thus may be difficult to interpret correctly.
Although four out of five isolates used for inoculation in the persistence experiments contained a (small) wild-type subpopulation, in at least one sample from each of the five experiments only the substitution was detectable by Sanger sequencing, indicating that the substitutions clearly dominated the viral population. The different substitutions persisted differently during the experiments ( Fig. 3a -e). The V116A ( Fig. 3a) and D199G ( Fig. 3e ) substitutions rapidly reverted to first mixed and subsequently wild-type genotype. In the persistence experiment using 51833/D199G, the R152K substitution emerged in addition to the D199G at 1 day p.i. in mixed genotype and was present until 6 days p.i., when it was no longer detected ( Fig. 3e ). In the 51833/ R152K persistence experiment, the R152K substitution seemed to persist longer, but was lastly observed the first day in the last generation of birds before being completely replaced by wild-type virus (Fig. 3c) .
Finally, the 51833/A138V and 51833/T157I substitutions ( Fig. 3b, d ) were detected as the dominant genotype more frequently than in the other three persistence experiments and were detectable in mixed or dominant genotypes throughout the entire experiments. Additional substitutions were detected in both experiments; the T131A substitution emerged in both experiments, while the T135N/S/I emerged in the 51833/T157I persistence experiment.
None of the five substitutions assessed in the persistence experiments dominated the genotype in both ducks at the end of any of the experiments, i.e. signs of reversion towards wild-type virus was detected in all persistence experiments.
Overall, 27 samples from the persistence experiments were selected for phenotypic drug susceptibility testing following isolation. Results are presented only for the isolates in which the mutated variants dominated the population and for the isolates used for inoculation in the birds (Table 2) . Isolates with any of the five substitutions and no additional NA substitutions exhibited a significantly higher IC 50 to ZA than the 58133/wt isolate (Table 3) .
Combined exposure and persistence experiment (OC-resistant 51833/H275Y) To assess the effect of ZA exposure to the stable OCresistant mutation H275Y, an experiment was performed where two mallards in generation one were inoculated with the OC-resistant isolate 51833/H275Y and exposed to increasing, and subsequently decreasing, concentrations of ZA in their water. The last three of the 16 generations of birds were not exposed to ZA at all (Fig. 1e) . Two resistance-related substitutions emerged during the experiment, R152K and D199G. Both were first detected occasionally in mixed genotype at 10 µg l À1 of ZA and later more frequently at 33.3 and 100 µg l À1 (Fig. 4) . The D199G substitution quickly reverted to wild-type when drug pressure was decreased, while the R152K substitution persisted in various proportions until complete reversion to wild-type was observed 4 days after the drug pressure was removed entirely. Regarding the H275Y substitution, only the H275Y variant and no wild-type was detected at amino acid residue 275 throughout the entire experiment.
Two additional substitutions emerged during the experiment. The A79T substitution was detected at 33.3 µg l À1 ZA and dominated the population completely by the end of the experiment. The V394I substitution was occasionally found in the first three and the last two generations of birds, and in addition in one sample at 33.3 µg l À1 ZA, exhibited mixed genotype in all but one sample. Since none of these substitutions affected drug susceptibility (see below), they are not included in Fig. 4 .
Drug susceptibility testing was performed on 14 isolates from the experiment (Table 4) . However, of these, six isolates containing only the A79T and V394I substitutions and no R152K or D199G substitution are excluded, since no effect of A79T or V394I on drug susceptibility was observed in these isolates (ZA IC 50 range=0.26-0.50 nM, P=0.0952, OC IC 50 range=510-660 nM, P=0.7143). In the drug susceptibility assay, the tested samples had a maintained high-level resistance to OC. Isolates containing the R152K and D199G substitutions exhibited fold changes in ZA IC 50 of 17.4 and 7.0, respectively, as compared to the wild-type virus (51833/ wt) and also exhibited a considerable increase in OC IC 50 (Table 4) . Isolates harbouring D199G and/or R152K had a significantly higher IC 50 as compared to isolates only 
DISCUSSION
This ZA exposure study assessed, firstly, emergence and persistence of ZA resistance in a wild-type H1N1 LPAIV, and, secondly, emergence and persistence of NAI resistance in a oseltamivir-resistant H1N1 LPAIV carrying the H275Y substitution. Multiple experiments in an in vivo mallard model were performed, mimicking the natural setting were LPAIVs of mallards may be exposed to environmental levels of ZA in the aquatic habitat of the birds.
Five different NA substitutions altering NAI susceptibility emerged in response to the ZA exposure, but did not persist in the absence of the drug. The H275Y substitution persisted both in the presence and absence of ZA. Additionally, two of the emerged substitutions, R152K and D199G, markedly enhanced the OC resistance conferred by the H275Y substitution.
Resistance development ZA treatment of IAV patients does not seem to easily generate resistant variants [34] [35] [36] [37] . This is likely explained by the high structural similarity of ZA to the natural NA sialic acid substrate, the lower use of this drug compared to oseltamivir and to the very high topical concentration delivered through inhalation [38, 39] . Furthermore, high-level resistance to ZA has proven difficult to detect when passaging H1N1 virus in the presence of the drug [40, 41] .
In our study, several resistance-related substitutions (V116A, A138V, R152K, T157I and D199G) emerged in response to ZA exposure. Increases in ZA IC 50 changes ranged from twofold to eightfold (wild-type IAV), and sevenfold to 17-fold (oseltamivir-resistant IAV), respectively. Most of the IC 50 of the isolates from either the exposure or persistence experiments did not meet the WHO criteria for reduced inhibition (10-100-fold increase in IC 50 ) [42] . Thus, our results correspond well with previous in vitro studies.
The mutations that emerged are situated on various parts of the neuraminidase protein. The amino acid residue 116 is situated close to the active site of the NA and may have an effect on Arg118, one of the three arginine residues that bind the carboxylate of sialic acid [43] . The V116A substitution has been observed in an N8 virus isolated from a wild mallard in Sweden and in a chicken H5N1 HPAIV in South East Asia [44, 45] . The V116A induced increase in ZA IC 50 observed in this study was similar to the levels previously described as a result of V116 substitutions [15, [44] [45] [46] [47] . The NA 199 position is a framework residue that stabilizes the active-site structure [48] . Substitutions at this position have previously been detected in patients both treated and not treated with NAIs and in influenza B viruses [49] [50] [51] [52] . Frequently, substitutions at the 199 position in N1 type viruses confer no or moderate reduction in ZA and OC susceptibility, with a few reports of more marked reduction [19, 50, [53] [54] [55] . Accordingly, in this study, a moderate increase in ZA IC 50 (sixfold for 51833/wt and sevenfold for 51833/H275Y) was conferred by D199G. The arginine at NA position 152 is a catalytic residue that interacts directly with the sialic acid substrate. Reports on the effects on IC 50 changes for NAIs when it is substituted are inconsistent [48, [56] [57] [58] [59] [60] . To our knowledge, the A138V and T157I substitutions have not previously been reported in IAVs.
The H275Y substitution in NA is the most widely reported OC resistance substitution, and in our mallard model it persisted also in the absence of drug pressure in a previous study [29] . In the current study, the H275Y substitution persisted throughout the experiment although no selective pressure for the mutation was present (i.e. no OC in the water, and no reduced sensitivity to ZA conferred by H275Y). H275Y was occasionally detected in combination with the R152K and D199G substitutions that, apart from decreasing susceptibility to ZA, markedly enhanced the OC resistance conferred by the H275Y substitution. Thus, firstly, ZA resistance can develop in an OC-resistant IAV while OC resistance is retained and, secondly, exposure of an OC-resistant IAV to ZA can result in an increase in OC resistance through synergistic mutations. These findings are concerning as ZA is the first-line treatment in the case of an outbreak of an oseltamivir-resistant IAV.
Measured environmental levels of ZA are well below (200-fold) the concentrations where resistance-related substitutions emerged in our study. However, only one wild-type mallard H1N1 LPAIV was assessed, making general conclusions on resistance-inducing concentrations in the environment and the fitness of such mutant viruses in other genetic makeups difficult, especially regarding LPAIVs of the N2 phylogenetic group as these NAs have distinct characteristics and resistance mutations. Also, to date, ZA use has been limited, and more extensive use in the future (e.g. due to oseltamivir resistance and/or more convenient formulations of ZA) could result in higher environmental concentrations.
In our experiments, we had a high variation of measured ZA water levels in samples taken just after addition of ZA to the pool water, from 0 to 98 % lower levels of ZA than intended, but never higher. Thus, we may have exposed the mallards and the IAVs to lower-than-intended levels of ZA in parts of the experiments, in that case overestimating the levels needed for resistance development. However, taken together, our findings indicate a low likelihood of ZA resistance development in the environment if the use of ZA does not increase dramatically. This is an important piece of information as it contrasts to earlier findings regarding oseltamivir [28] [29] [30] [31] [32] , and indicates ZA as a better treatment choice from an environmental resistance development perspective.
Persistence
None of the resistance-related substitutions that emerged during ZA exposure in this study persisted in the absence of the drug. These results suggest reduced viral fitness of the mutations in our genetic makeup, as wild-type virus managed to outcompete the mutant sub-populations relatively quickly, i.e. in a limited evolutionary space. Thus, our experiments did not indicate that ZA resistance can persist without drug pressure in the environment, but some previous work demonstrates that persistence per se is possible under some circumstances. In A(H1N1)pdm09 passaged in mice, the D199N substitution alone and in combination with H275Y persisted, in contrast to the R152K substitution where a mixed population with wild-type sequence was observed [58] . The V116A substitution in an H5N1 has been reported to persist during replication in ferrets and to grow to titres comparable to wild-type virus in MDCK cells [46] . Furthermore, we tested only one strain of wild-type LPAI H1N1, thus persistence in a different genetic makeup in another strain from the N1-phylogenetic group cannot be categorically excluded. However, in comparison to oseltamivir which induced resistance that persisted without drug pressure in the same 51833/wt LPAIV, ZA seems more favourable than oseltamivir from an environmental resistance development perspective.
The T131A substitution emerged in both 51833/A138V and 51833/T157I persistence experiments, and the T135 N/S/I substitution emerged in the latter. Isolates with a dominant T157I substitution in addition to either the T131A or T135 N/S/I or a combination, exhibited ZA IC 50 comparable to that of the 51833/wt. These substitutions thus appeared to increase ZA susceptibility and restore the wild-type phenotype. We hypothesize that the acquisition of the T131A or T135 N/S/I substitutions represents a second evolutionary path to restore viral fitness in response to decreased ZA pressure, apart from reverting the resistance-related substitutions to wild-type.
In contrast to the instability of the ZA-related substitutions, the H275Y substitution conferring OC resistance persisted throughout the extensive H275Y experiment, in the absence of any selective pressure (as H275Y does not confer a decrease in ZA susceptibility). Thus, this study further reinforces previous data of the persistence of the substitution in the absence of drug pressure and thus its retained fitness.
Conclusion
Our results indicate less potential for development and persistence of resistance due to ZA than OC in an environmental setting. This conclusion is based on a lower increase in ZA IC 50 conferred by the mutations caused by ZA exposure, and that higher ZA water concentrations were needed to induce resistance -considering the present use of ZA environmental resistance development is highly unlikely in the tested LPAIV. Further, ZA resistance did not persist without drug pressure, and the multiple resistance-related substitutions seen during ZA exposure suggest lack of one straight-forward evolutionary path to resistance. However, further studies confirming our findings are recommended, especially using LPAI viruses of the N2-phylogenetic group of NAs, as they have distinctly different structural characteristics and can accommodate resistance differently. Our study adds further evidence regarding the stability of the oseltamivir-induced substitution H275Y without drug pressure, and demonstrates the ability of a H275Y-carrying IAV to acquire secondary mutations further boosting OC resistance when exposed to ZA. Given the crucial importance of NAIs in pandemic preparedness and the potential for resistance development in the natural host in the environment due to drug residue pollution, limiting NAI use and improving sewage treatment to better degrade NAIs remain top priorities; our study indicates this is especially important with regard to oseltamivir.
METHODS Viruses
The LPAIV A/mallard/Sweden/51833/2006 (H1N1) (51833/ wt), was originally isolated from a wild mallard trapped in Southern Sweden (NA GenBank accession: AEA02276).
The mutant A/mallard/Sweden/51833/2006 (H1N1)/NA-H275Y (51833/H275Y), was isolated from a mallard inoculated with 51833/wt and exposed to 80 µg l À1 OC in the water in a previous experiment [28] . The NA mutation H275Y confers resistance to OC, in this particular IAV with an approximately 330-fold increase of the IC 50 [28] .
All viruses were isolated in 11-day-old specific-pathogen-free embryonated chicken eggs (Valo, Germany). Swab samples from experimental birds were inoculated via the allantoic route, and allantoic fluid was harvested after 2 days and tested by haemagglutination using chicken erythrocytes (Lohmann Tierzucht, Cuxhaven, Germany).
Drugs
ZA used in the exposure experiments was purchased locally as Relenza which was dissolved in double distilled water and stored as stock solution in À20 C. In the persistence and H275Y experiments, ZA used for exposure and neuraminidase inhibition assay, and a 
Mallard model
Mallards were purchased from a commercial breeder and delivered one day after hatching. They were reared in captivity, and experiments were performed at the Swedish National Veterinary Institute.
To confirm the absence of previous infection with IAV, blood samples were collected from all birds at 10 weeks of age and assessed for anti-IAV antibodies by a commercially available ELISA according to the manufacturer's recommendations (FlockCheck, Avian Influenza Virus Antibody Test Kit, IDEXX, Hoofddorp, The Netherlands). In addition, faecal samples were collected prior to inclusion in the experiments to detect active shedding of IAV by real-time PCR as described below.
Largely, all experiments had a similar design. Following oesophageal inoculation of the first two mallards (generation one) with LPAIV, the birds resided in the experimental room with a 170 l pool as their sole water source. The pool water was changed once daily and ZA was added at a specified concentration. Then, 3 days p.i., two naive birds (generation two) were added to the room, allowing natural transmission between the two generations and continued viral replication. At 5 days p.i., generation one was euthanized by administration of sodium pentobarbital [100 mg Pentobarbital vet. (100 mg ml À1 ) per kg of body weight] intravenously. Depending on the design of the specific experiment, additional generations were added in the same overlapping manner 24 h after removal of previous generations (Fig. 1a-e) .
Three categories of experiments were undertaken. First, three drug exposure experiments were performed, where ZA concentration in the water of the birds was 1, 10 or 100 µg l
À1
, here referred to as the exposure experiments (Fig. 1a-c) . For technical reasons, the three ZA exposure experiments were not identical regarding the number of birds and the length of the experiments. Second, in order to assess the persistence of the mutations that emerged in the first set of experiments, five identical follow-up experiments were performed, referred to as the persistence experiments (Fig. 1d) . Here, the viruses with the reduced ZA susceptibility were allowed to replicate while the drug pressure was gradually removed. A rapid decrease in ZA concentration during the first 3 days of the experiments was followed by 8 days with no ZA exposure.
Finally, a combined exposure and persistence experiment using the OC-resistant 51833/H275Y AIV (hereafter referred to as the H275Y experiment) was performed where generation one was inoculated with 51833/H275Y (Fig. 1e) . This experiment included 16 generations of birds exposed to successively increasing followed by decreasing concentrations of ZA concentration in the water. At the start 1 µg l
of ZA was used for 5 days, followed by 3.3, 10 and 33 µg l
at each level for 6 days, 100 µg l À1 for 9 days, 10 and 1 µg l À1 for 3 days at each level and finally 0 µg l À1 for 12 days.
Faecal sampling
Faecal samples were collected daily from all birds. The birds were put in single-use cardboard boxes from where their droppings were sampled using a sterile-tipped swab. The swab was placed in viral transport media and the samples were stored at À70 C within 2 h of collection. Cloacal samples were collected on the rare occasions when a bird did not defecate in the cardboard box.
Detection of virus and sequencing of the NA gene RNA from the exposure experiments was extracted using the Magnatrix 8000 extraction robot (Magnetic Biosolutions, Stockholm, Sweden) and Vet Viral NA kit (NorDiag ASA, Oslo, Norway). RNA from the persistence and H275Y experiments was extracted in a Maxwell 16 Research Instrument (Promega, Fitchburg, WI, USA), using the Maxwell 16 Viral Total Nucleic Acid Purification Kit, according to the manufacturer's instructions. If no IAV was detected in the extracts from the exposure experiments, the samples were re-extracted in the Maxwell instrument for confirmation.
Detection and semi-quantification of viral load in the samples and isolates were performed in a Corbett Rotor-Gene 2000 thermo cycler (Qiagen, Hilden, Germany) using the iScript one-step reverse transcriptase PCR kit for probes (Bio-Rad, Hercules, CA, USA) in a real-time reverse transcriptase-PCR targeting the matrix gene [61] . Samples with a cycle threshold value below 40 were considered positive.
The NA gene in IAV-positive samples was targeted in a one-step reverse transcriptase-PCR using a Superscript III PCR products were purified using ExoSAP-IT (Affymetrix, CA, USA) and sequenced at Macrogen (Seoul, South Korea). Sequence analysis was performed in SeqScape software, version 2.7 (Applied Biosystems/Thermo Fisher Scientific, Waltham, MA, USA) using the sequence for 51833/ wt as a reference. A sequence result was considered reliable if there were at least two high-quality electropherogram sequences at a given nucleotide position. If not, the sequence result was referred to as 'no sequence acquired'. The genotype was determined as 'mixed' if two peaks representing different nucleotides were visible at a single position in the electropherograms, and 'dominant' if only one peak was visible.
Neuraminidase inhibition testing Phenotypic susceptibility to NAIs was assessed by the functional NA inhibition assay using the fluorogenic 2-(4-methylumbelliferyl)-a-D-N-acetylneuraminic acid (MUNANA) substrate (Sigma-Aldrich, St Louis, MO, USA). Selected samples from the experiments were propagated in specificpathogen-free embryonated chicken eggs as previously described, and the NA gene of the isolates was sequenced to assess genotype consistency between the isolate and the experimental sample. The isolates were subjected to NA inhibition by OC and ZA in duplicate samples in 96-well plates, observing the protocol of the European Vigilance Network for the management of antiviral drug resistance (VIRGIL-CLINVIR) [62] . Fluorescence was measured in an Infinite M1000 PRO micro plate reader (Tecan Group, Zür-ich, Switzerland), and the IC 50 were determined from the best-fit dose-response curves using Prism 6 software (GraphPad Software, La Jolla, CA, USA).
Statistical analysis
Hypothesis testing of equality of IC 50 results and NA activity of mutant to wild-type isolates was performed using the Mann-Whitney non-parametric U test (Prism 6 software, GraphPad).
Sampling and analysis of experimental water concentrations See Supplementary Material. . GlaxoSmithKline contributed zanamivir and isotope-labelled zanamivir, and Roche contributed oseltamivir carboxylate used in this study. None of the funders had any role in the design or execution of the study, or in the interpretation of data.
